Cannabis is thriving in the US, and it’s about to enter a critical time as Americans prepare to vote.

With the US presidential election right around the corner, the Investing News Network (INN) talked with a few experts to determine what investors can expect regardless of the outcome.

The presidential election this year will see President Donald Trump face off against Joe Biden, Democratic nominee and former vice president. On November 3, voters will cast their ballots to decide whether or not Trump gets another four years in office.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

In this article, INN examines the ways the cannabis business may move forward in the case of a Trump re-election. Click here for our coverage of what could happen in the event of a Biden victory.

The Trump administration’s history with cannabis

Sentiment on the cannabis industry was mixed in the US after Trump’s win in 2016 — after all, Canada had yet to legalize the drug for recreational use, a move that has since paved the way forward by offering a roadmap to approach the novel drug industry.

During his campaign, Trump had sent mixed signals as to his personal level of interest in terms of cannabis policy, and after his election the confusion continued.

The biggest opposition and real moment of concern for the US industry came as Trump’s first attorney general, Jeff Sessions, reinforced his strong stance against the drug and its legalization at any level.

The disdain for cannabis from Sessions began early and included the infamous phrase, “good people don’t smoke marijuana,” said during a Senate hearing in April 2016.

Sessions’ biggest aggression against cannabis came early in 2018, when he removed a technical federal protection for cannabis state programs, enacted during the second term of Trump’s predecessor, Barack Obama. At the time, this decision sent cannabis stocks tumbling, a clear sign of the concern investors held about the impact Sessions could have on the marijuana industry and its growth.

In November 2018, Sessions resigned as attorney general, a move that again moved the needle for cannabis investments, only this time the trend was upwards.

Sessions’ departure was so well received by the industry that a room of investors even clapped and cheered to the sound of Sessions leaving the Trump administration.

Trump’s back and forth with cannabis didn’t end there, as he’s made comments on the development of cannabis regulation bills, including the STATES Act.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“I know exactly what (Colorado Senator Cory Gardner) is doing. We’re looking at it,” said Trump in mid-2018. “But I probably will end up supporting that, yes.”

Most recently, US Congress has been pushing for a vote on the MORE Act, which would deschedule cannabis under the federal government perspective.

However, like the STATES Act before it, the new legislation is expected to stall at the Senate due to the majority leadership of Republican Senator Mitch McConnell. That would prevent the bill from getting a signature from Trump and being enacted.

What does Trump think about cannabis now?

Earlier this year, a report in the Chicago Tribune indicated that according to Trump’s campaign spokesman, Marc Lotter, the president maintains a conservative mindset for the drug.

“I think the president is looking at this from a standpoint of a parent — a parent of a young person — to make sure we keep our kids away from drugs,” Lotter said at the time.

“They need to be kept illegal, that is the federal policy.”

Matt Carr, chief trends strategist at the Oxford Club, told INN that in the event of a Trump re-election he expects cannabis businesses, particularly at the state level, to continue at the same pace.

Effectively, given the lack of a federal framework, individual states have tackled the cannabis industry by either directly enacting policies or by leaving the issue to voters and asking them to determine whether or not to move forward with state programs.

This version of the market has created a fractured rollout in which no intrastate commerce is allowed. What’s more, for the companies big enough to operate in multiple states, every operation can feel like a totally different corporation.

“If Trump wins, do we have federal legalization in the next couple years? Probably not,” Carr said. “Because I think they control the White House and then the Senate; that’s kind of difficult.”

Despite these challenges, multi-state operators have established a footprint while engaging investors and gaining ground in conversations around best bets on cannabis stocks.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

While being excited about the potential for federal reform, a duo of cannabis experts at fund manager Purpose Investments aren’t holding their breath for big changes given that cannabis in the US is growing with or without policy changes.

In a note issued to investors, Greg Taylor, chief investment officer and portfolio manager with Purpose Investments, alongside portfolio manager Nawan Butt, wrote:

Although there may be hurdles in cannabis reform in the US, the trajectory of current sales growth is unaffected by this. We continue to see outsized growth in most states as operators have worked out how to optimize within the current constraints. Any reform at the federal level will cause a step function in valuations of these operators, but explosive growth can still continue under current regulations.

An exchange-traded fund (ETF) manager agrees with Taylor and Butt. “Even if Trump were to win somehow, it’s not a negative for marijuana and at least has all the upside it already has right now,” Dan Ahrens, managing director and chief operating officer with AdvisorShares, told INN.

Ahrens manages the AdvisorShares Pure Cannabis ETF (ARCA:YOLO), which engages with US-operating companies publicly listed in the Canadian markets.

The ETF manager expects to see cannabis as a conversation topic this election cycle, regardless of the final result, since five states will be voting on the advancement of cannabis programs.

Investor takeaway

Trump has become an unpredictable figure, and while that has helped spread ideas about the potential for his administration to work on cannabis policy at the federal level, little has come of it.

Whether or not Trump engages with the cannabis industry — for good or bad — remains to be seen.

But experts agree that given a second term of Trump, cannabis will likely remain untouched by federal powers, meaning state programs and the companies working within them will continue to operate and even thrive with growing sales.

The growth of the industry seems poised to continue with or without Trump at the helm of the country.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!


Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less